Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study.
BACKGROUND
Helicobacter pylori infection is associated with gastric ulcer disease in about 75% of cases.


OBJECTIVE
The aim of this study was to determine whether H. pylori eradication reduces gastric ulcer relapse rates.


METHODS
The study was randomized, controlled, multicentric and investigator blinded, and was conducted at three university hospitals, two teaching hospitals, and by six practising gastroenterologists.


METHODS
During a period of 1 year 152 patients with gastric ulcers were randomly assigned to one of two treatment regimens: omeprazole 20 mg daily in the morning for 8 weeks (74 patients), or bismuth subsalicylate 600 mg three times daily for 8 weeks combined with 500 mg amoxicillin twice daily and 1000 mg tinidazole twice daily for the first 10 days (triple therapy) (78 patients). Follow-up examinations were performed 6, 12 and 18 months after treatment and whenever ulcer symptoms occurred.


RESULTS
Of the 152 randomized patients five were excluded because of gastric cancer, 10 missed follow-up examinations and seven receiving triple therapy terminated treatment because of side effects. Of the remaining 130 patients, five of 69 (7.2%) in the omeprazole and six of 61 (9.8%) in the triple group were H. pylori negative. After 8 weeks' therapy, the gastric ulcer was healed in 85.9% (omeprazole) and in 81.8% triple) in H. pylori-positive patients, and in 80% (omeprazole) and 16.7% (triple) in H. pylori-negatives. H. pylori was eradicated in 8.1% of the patients who received omeprazole monotherapy and in 78.2% receiving triple therapy, and in 8.1% and 69.4% in an intention-to-treat analysis. The subsequent relapse rates during a follow-up period of 12 months were 50% in the omeprazole group and 4% in the triple group. Gastric ulcer relapse was observed in 49% of patients who were H. pylori positive and in 2% who were H. pylori negative after treatment.


CONCLUSIONS
The data show that the presence of H. pylori is an important predictor of gastric ulcer relapse and that eradication of H. pylori may heal gastric ulcer disease.
Bayerdörffer
E
E
Department of Gastroenterology, Hepatology and Infectious Diseases, Otto v. Guericke University, Magdeburg, Germany.
Miehlke
S
S
Lehn
N
N
Mannes
G A
GA
Höchter
W
W
Weingart
J
J
Klann
H
H
Sommer
A
A
Heldwein
W
W
Hatz
R
R
Simon
T
T
Bolle
K H
KH
Bästlein
E
E
Meining
A
A
Ruckdeschel
G
G
Stolte
M
M
D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001706:Biopsy; D001729:Bismuth / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use*; D012008:Recurrence; D012459:Salicylates / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000382:microbiology* / Q000517:prevention & control; D013997:Time Factors; D014011:Tinidazole / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D010406:Penicillins; D012459:Salicylates; D014011:Tinidazole; C015715:bismuth subsalicylate; D000658:Amoxicillin; D009853:Omeprazole; D001729:Bismuth